전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved87 programs
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

GSK 5733584 + Dostarlimab (GSK 5733584 + Dostarlimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
CGTLimited DatastaleCelgenePhase 3

Gene-modified (GM, Gene-modified, Gene-modified (GM) T cell therapy)

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCancer Research UKPhase 2

atezolizumab (Tecentriq, HTL0039732 Capsules and atezolizumab infusion)

Neoplasms; Prostatic Neoplasms, Castration-Resistant · Neoplasms

#Neoplasms#Antibody#Phase2#monoclonal-antibody#ProstaticNeoplasms+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Herceptin (trastuzumab))

Breast Neoplasms · Breast Neoplasms

#BreastNeoplasms#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Discontinued
CGTLimited DatastaleZhejiang UniversityPhase 1

IL-5 CAR-T cells (IL-5 CAR-T cells)

Hematologic Diseases; Neoplasms · Hematologic Diseases

#HematologicDiseases#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLiping DouPhase 1

In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (In vivo BCMA/GPRC5D Tandem Dual CAR-T cell)

Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleBayerPhase 1

BAY1129980 (Lupartumab Amadotin, Lupartumab Amadotin (BAY1129980))

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#Bayer
Trials 1Status Discontinued
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

NUC-3373 + bevacizumab (NUC-3373 + bevacizumab)

Colorectal Cancer; Colorectal Neoplasms · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ColorectalNeoplasms+1
Trials 1Status Active
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 1

P-PSMA-101 CAR-T cells (P-PSMA-101 CAR-T cells)

Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePreclinical

neoadjuvant (Pertuzumab, Pertuzumab (neoadjuvant))

HER2-positive Breast Cancer; Neoplasms · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 1

atezolizumab (Tecentriq, RO7567132 and Atezolizumab)

Cancer-Neoplasms · Cancer-Neoplasms

#Cancer-Neoplasms#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 1Status Recruiting
AntibodyLimited DatastaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#monoclonal-antibody#OncolyticVirotherapy+1
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar))

Breast Neoplasms · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#BreastNeoplasms+1
Trials 1Status Discontinued
CGTLimited DatastalesuhaichuanPreclinical

TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy (TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy)

Advanced Solid Tumor; Neoplasms · Advanced Solid Tumor

#AdvancedSolidTumor#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 3

JS001 (Toripalimab, Toripalimab (JS001 ))

Urinary Bladder Neoplasms · Urinary Bladder Neoplasms

#UrinaryBladderNeoplasms#Antibody#Phase3#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, Trilaciclib with or without trastuzumab + pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Recruiting
CGTLimited DatastaleIntima Bioscience, Inc.Phase 2

TIL (Tumor-Infiltrating Lymphocytes, Tumor-Infiltrating Lymphocytes (TIL))

Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms · Gastrointestinal Epithelial Cancer

#GastrointestinalEpithelialCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active

4 / 5 pages

← PreviousNext →